BRIEF-Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide

Reuters02-10

BRIEF-Kailera <a href="https://laohu8.com/S/LENZ">Therapeutics</a> & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide

Feb 10 (Reuters) - KAILERA THERAPEUTICS:

KAILERA THERAPEUTICS: CO, HENGRUI PHARMA REPORT POSITIVE TOPLINE DATA FROM PHASE 2 OBESITY TRIAL OF ORAL RIBUPATIDE
KAILERA THERAPEUTICS: MEAN WEIGHT LOSS OF UP TO 12.1% WITH NO OBSERVED PLATEAU AT 26 WEEKS IN PHASE 2 TRIAL IN CHINA WITH ORAL RIBUPATIDE
KAILERA THERAPEUTICS: HENGRUI TO TEST ORAL RIBUPATIDE IN PHASE 3 TRIAL IN CHINA; CO PLANS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL IN 2026

Further company coverage: 600276.SS

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610642085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610642085","market":"us","top_or_hot":-1,"title":"BRIEF-Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Kailera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> &amp; Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide</title></head><body><p><span>Feb 10 (Reuters)</span><span> - </span>KAILERA THERAPEUTICS: </p><ul><li><p>KAILERA THERAPEUTICS: CO, HENGRUI PHARMA REPORT POSITIVE TOPLINE DATA FROM PHASE 2 OBESITY TRIAL OF ORAL RIBUPATIDE</p></li><li><p>KAILERA THERAPEUTICS: MEAN WEIGHT LOSS OF UP TO 12.1% WITH NO OBSERVED PLATEAU AT 26 WEEKS IN PHASE 2 TRIAL IN CHINA WITH ORAL RIBUPATIDE</p></li><li><p>KAILERA THERAPEUTICS: HENGRUI TO TEST ORAL RIBUPATIDE IN PHASE 3 TRIAL IN CHINA; CO PLANS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL IN 2026</p></li></ul><p>Further company coverage: <span>600276.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Kailera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> &amp; Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide</title></head><body><p><span>Feb 10 (Reuters)</span><span> - </span>KAILERA THERAPEUTICS: </p><ul><li><p>KAILERA THERAPEUTICS: CO, HENGRUI PHARMA REPORT POSITIVE TOPLINE DATA FROM PHASE 2 OBESITY TRIAL OF ORAL RIBUPATIDE</p></li><li><p>KAILERA THERAPEUTICS: MEAN WEIGHT LOSS OF UP TO 12.1% WITH NO OBSERVED PLATEAU AT 26 WEEKS IN PHASE 2 TRIAL IN CHINA WITH ORAL RIBUPATIDE</p></li><li><p>KAILERA THERAPEUTICS: HENGRUI TO TEST ORAL RIBUPATIDE IN PHASE 3 TRIAL IN CHINA; CO PLANS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL IN 2026</p></li></ul><p>Further company coverage: <span>600276.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nP8N3OV045:1","article_id":"2610642085","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610642085","pubTimestamp":1770724805,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral RibupatideFeb 10  - KAILERA THERAPEUTICS: KAILERA THERAPEUTICS: CO, HENGRUI PHARMA REPORT POSITIVE TOPLINE DATA FROM PHASE 2 OBESITY TRIAL OF ORAL RIBUPATIDEKAILERA THERAPEUTICS: MEAN WEIGHT LOSS OF UP TO 12.1% WITH NO OBSERVED PLATEAU AT 26 WEEKS IN PHASE 2 TRIAL IN CHINA WITH ORAL RIBUPATIDEKAILERA THERAPEUTICS: HENGRUI TO TEST ORAL RIBUPATIDE IN PHASE 3 TRIAL IN CHINA; CO PLANS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL IN 2026Further company coverage: 600276.SS ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","BK0196":"行业龙头","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0239":"医药制造","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK0183":"MSCI概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0188":"融资融券","BK0012":"证金概念","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","BK0028":"国家队","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0060":"抗癌","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"translate_title":"简介-Kailera Therapeutics和恒瑞医药报告口服利布肽2期肥胖试验的积极顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9},"content_text":"BRIEF-Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral RibupatideFeb 10 (Reuters) - KAILERA THERAPEUTICS: KAILERA THERAPEUTICS: CO, HENGRUI PHARMA REPORT POSITIVE TOPLINE DATA FROM PHASE 2 OBESITY TRIAL OF ORAL RIBUPATIDEKAILERA THERAPEUTICS: MEAN WEIGHT LOSS OF UP TO 12.1% WITH NO OBSERVED PLATEAU AT 26 WEEKS IN PHASE 2 TRIAL IN CHINA WITH ORAL RIBUPATIDEKAILERA THERAPEUTICS: HENGRUI TO TEST ORAL RIBUPATIDE IN PHASE 3 TRIAL IN CHINA; CO PLANS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL IN 2026Further company coverage: 600276.SS ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610642085","isCrawlerRequest":true}